KR20160026443A - Compositions for improving skin wrinkle or enhancing skin elasticity comprising loganic acid - Google Patents

Abstract

The present invention relates to a composition, particularly a cosmetic composition, a food or a pharmaceutical composition, which relates to the improvement of skin wrinkles or skin elasticity, and relates to a cosmetic composition, a food or a pharmaceutical composition excellent in skin wrinkle and skin elasticity . The cosmetic, food or pharmaceutical composition of the present invention comprises loganic acid which has a strong synthesis promoting activity of collagen, especially type 1 and type 3 collagen, and is excellent in skin wrinkle improvement and skin elasticity enhancement effect Do. In addition, rosiglucanic acid is excellent in stability and harmless to the human body, and a cosmetic, food, or pharmaceutical composition containing the rosigonic acid is easy to formulate and has excellent formulation stability.

Description

[0001] The present invention relates to a composition for improving skin wrinkles or enhancing skin elasticity comprising rosiglucan,

The present invention relates to a composition, particularly a cosmetic composition, a food or a pharmaceutical composition, which relates to the improvement of skin wrinkles or skin elasticity, and relates to a cosmetic composition, a food or a pharmaceutical composition excellent in skin wrinkle and skin elasticity .

Skin is an important organ that is responsible for various physiological functions such as barrier function, body temperature control, or excretion, which protects the human body from the external environment and prevents the internal moisture and useful components from flowing out. Generally, the skin is more prone to wrinkles than other organs because it has many opportunities to interact with various external stimuli. Among them, facial skin is exposed directly to sunlight, dry environment, pollutants, etc., so that aging phenomenon such as wrinkles occurs earlier than skin not exposed to the outside.

The most characteristic change due to aging of the skin tissue is a change in the skin matrix, which causes aging of the human skin fibroblast in the dermis, resulting in a decrease in the ability to produce fibrous and matrix. The amount of the substrate is generally decreased, and the thickness of the skin is thinned, and the elasticity of the skin is lowered and wrinkles are formed. That is, as the skin ages, the skin becomes less elastic, the blood circulation becomes disordered, or the skin barrier becomes weaker.

Collagen is a major substrate protein produced in the fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of the skin, resistance of connective tissues and binding force of tissues, and support through adhesion between cells. . Collagen is a major protein that accounts for about 30% of the total biomass protein weight and has a solid triple helix structure. Collagen forms most of the organic matter in the skin, tendons, bones and teeth, especially in the bones and skin (dermis). Type I collagen (type I collagen) and type III collagen (type III collagen) are present in the skin. Among them, type 1 collagen accounts for a large portion and type 3 collagen is small, but both types of collagen are reduced by external stimuli such as age and ultraviolet rays, and this is closely related to the formation of wrinkles of the skin It is known.

In the prior art, there have been products in which collagen is formulated into cosmetics using the skin moisturizing effect of collagen. However, since these cosmetics are coated with collagen on the skin surface, transdermal absorption of collagen as a polymer is very difficult, It is difficult to expect the action, so it can not be said that improvement of essential skin function.

Conventional collagen synthesis promoting substances include retinoic acid, transforming growth factor (TGF) (Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974), animal placenta (Japanese Patent Application Laid-Open No. 8-231370), betulinic acid (Japanese Patent Application Laid-Open No. 8-208424), chlorella extract (Japanese Patent Application Laid-Open No. 9-40523, Japanese Laid-Open Patent Application No. 10-36283, Many materials are known. However, when these substances are applied to the skin, there is a limitation in use due to safety issues such as irritation and redness, or the effect of improving the skin function can not be expected because the effect is insignificant. Therefore, it is urgently required to develop a cosmetic composition for improving skin wrinkles, which is safer and more effective for a living body than a conventional skin wrinkle improving cosmetic composition.

Therefore, a problem to be solved by the present invention is to solve the above-mentioned problems, and to provide a new active ingredient which is low in side effects and safe for human body, and which is excellent in skin improvement, particularly skin wrinkle improvement or skin elasticity improvement effect, .

In other words, a problem to be solved by the present invention is to provide a composition comprising an active ingredient having excellent efficacy as an active ingredient.

In order to solve the above problems, the present invention provides a composition comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

More specifically, the present invention provides an external preparation for skin comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention provides a cosmetic composition comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention provides a composition for improving skin wrinkles or skin elasticity, preferably a cosmetic, a food or a pharmaceutical composition comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Preferably, the present invention provides a new use for the improvement of skin wrinkles or skin elasticity of loganic acid or a pharmaceutically acceptable salt thereof.

The inventors of the present invention have made intensive efforts to develop a substance having an effect of promoting collagen synthesis safely in a human body in a small amount, and as a result, it has been found that loganic acid is very effective for both type 1 and type 3 collagen And that it can be used for skin improvement, in particular wrinkle improvement or skin elasticity enhancement, thereby completing the present invention.

In the present invention, " skin improvement " refers to favorable effects of rosiglucanic acid absorbed by the skin, and the beneficial effect on the skin means that the skin condition and / or function is maintained and improved. For example, Promoting collagen synthesis and thereby improving skin wrinkles or skin elasticity.

In the present invention, 'skin wrinkles' refers to small lines formed by aging of skin, which may be caused by genes, by reduction of collagen and elastin present in skin dermis, or by external environment.

In the present invention, " improvement of skin wrinkles " means suppressing or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.

In the present invention, "skin elasticity" is represented by elastic fibers composed of elastin existing in the dermal layer. Such elastic fibers have a very low elastic modulus such as rubber and are easily deformed by a small force, When removed, it easily returns to the original shape. Elastic fibers have a structure in which microfibirls are embedded in an amorphous substrate called elastin. Elastin is a very unique substance found only in the elastic fibers of lysine-derived desmosine and isodesmosine It is a protein composed of amino acids. These desmosins and isodesmesynes form cross-links in long peptide chains, which makes elastin behave like a rubber.

In the present invention, 'skin elasticity enhancement' refers to elasticity fibers composed of elastin together with collagen fibers, which improve skin elasticity in a state where elastin and collagen are present sufficiently .

More specifically, the present invention provides a composition comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.

[Chemical Formula 1]

The compound represented by Formula 1 is loganic acid and may include all possible isomers.

The present invention is not particularly limited to the method for obtaining the rosigonic acid, and it can be obtained by general chemical synthesis, separated from natural products, or sold.

As the active ingredient of the composition of the present invention, the loganic acid may be used in the form of a pharmaceutically acceptable salt thereof, and may be used as a pharmaceutically acceptable metal salt using a base. In the case of an alkali metal or an alkaline earth metal salt, the compound can be obtained by dissolving the compound in an excess amount of an alkali metal hydroxide or an alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, as the metal salt, sodium, potassium, calcium salt and the like are preferably formulated for pharmaceuticals, but the present invention is not limited thereto. The corresponding silver salt can also be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

The pharmaceutically acceptable salts of the loganic acid may include salts of acidic or basic groups that may be present in the compounds of loganic acid, unless otherwise indicated. Pharmaceutically acceptable salts may include, for example, the sodium, calcium, or potassium salts of the hydroxy group, and the other pharmaceutically acceptable salts of the amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate (Hydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), or p-toluenesulfonate (tosylate) salts, Can be prepared through a method for producing a salt to be used.

In the present invention, the loganic acid may include derivatives thereof having the same effect. The loganic acid may also contain a solvent or hydrate which exhibits the same efficacy as can be prepared therefrom.

The loganic acid of the present invention can be used as a promoter of collagen synthesis.

The composition comprising the loganic acid of the present invention promotes the synthesis of collagen, more specifically type 1 collagen (type I collagen) and type 3 collagen (type III collagen), thereby improving skin wrinkles or skin elasticity And exhibits an enhancing effect. In the examples of the present invention, after the composition of the present invention was administered to a culture medium of human-derived fibroblasts, the amounts of the biosynthesized collagen were measured. As a result, the loganic acid concentration Type collagen and type 3 collagen were found to be superior to human-derived fibroblasts (Example 1, Example 2, Table 2, Table 3). In the example of this nickname, the wrinkle improvement effect was evaluated through image analysis of under-eye wrinkles. As a result, the region treated with loganic acid showed a wrinkle improvement effect superior to that of the control group (untreated) (Example 4, Table 8).

The present invention provides a cosmetic composition for improving skin wrinkles or skin elasticity comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The cosmetic composition of the present invention may contain loganic acid in an amount of 1 × 10 ^-6 to 10% by weight, more preferably 0.001 to 10% by weight, most preferably 0.1 to 10% by weight, 10% by weight. When the content is less than ¹ x ^10-6 wt%, no significant effect can be expected. When the content is more than 10 wt%, the effect is not increased more than the content increase.

The cosmetic composition for improving skin wrinkles or improving skin elasticity according to the present invention can be used as a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening water, a pack, a soft water, a milky lotion, a makeup base, an essence, a soap, But are not limited to, those selected from the group consisting of screen cream, sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, But are not limited thereto.

In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier incorporated in a cosmetic composition for general skin, and examples thereof include oil, water, a surfactant, a moisturizer, a lower alcohol, A thickener, a chelating agent, a coloring matter, a preservative, and a perfume, but the present invention is not limited thereto.

The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulations. When the formulation of the cosmetic composition of the present invention is an external ointment, paste, cream, or gel, it is preferable to use an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, , Zinc oxide, or a mixture thereof, and the like can be used.

When the formulation of the cosmetic of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof, Propellants such as chlorofluorohydrocarbons, propane / butane, dimethyl ether, and the like may additionally be included.

When the formulation of the cosmetic of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent may be used as a carrier component. More specifically, when the cosmetic formulation is a solution or an emulsion, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, cotton seed oil, peanut oil, corn oil , Olive oil, castor oil, sesame oil, glycerol aliphatic ester, polyethylene glycol, sorbitan fatty acid ester, and the like.

When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol, and propylene glycol as a carrier component; Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; And at least one selected from the group consisting of microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, and tracant.

When the formulation of the cosmetic composition of the present invention is a soap, the carrier component includes an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, an isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, May be used.

The cosmetic composition of the present invention may further comprise at least one substance having the function of improving skin wrinkles or improving skin elasticity.

The present invention provides a food composition for improving skin wrinkles or skin elasticity comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Foods containing the compounds of the present invention include, for example, various foods, beverages, gums, tea, and vitamin complexes, but are not limited thereto. In addition, the food of the present invention may be in the form of tablets, capsules, pills, liquids and the like.

The beverage composition for improving skin wrinkles of the present invention is not particularly limited to other ingredients except for containing the above-mentioned compound as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient have. Such natural carbohydrates include, for example, monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose and the like; Polysaccharides such as dextrin and cyclodextrin; And sugar alcohols such as xylitol, sorbitol, erythritol, and the like. As the flavorings other than the above, natural flavors such as tau Martin and stevia extract (rebaudioside A, glycyrrhizin, etc.) or synthetic flavors such as saccharin and aspartame may be used. The natural carbohydrate may be included in an amount of generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition.

The food composition of the present invention can also be used as a nutritional supplement, a vitamin, a mineral (electrolyte), a synthetic flavor, a natural flavor, a colorant, a thickening agent (cheese, chocolate etc.), a pectic acid or a salt thereof, A colloid thickening agent, a pH adjusting agent, a stabilizer, a preservative, glycerin, an alcohol, and a carbonating agent. The food composition of the present invention may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The content of such an additive is not particularly limited and may be usually 0 to 20 parts by weight based on the total weight of the food composition.

The present invention provides a pharmaceutical composition for improving skin wrinkles or skin elasticity comprising loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

In the present invention, the pharmaceutical composition is selected from the group consisting of ointments, creams, tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, aqueous solutions, nonaqueous solutions, suspensions, And may be formulated, but is not limited thereto.

In the present invention, the pharmaceutical composition may be various formulations such as oral or parenteral. When the pharmaceutical composition is formulated, it may be prepared using at least one selected from the group consisting of conventional fillers, extenders, binders, wetting agents, disintegrants, diluents such as surfactants, and excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like. Such solid preparations may contain, for example, at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, ≪ / RTI > In addition to excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration may include suspensions, solutions, emulsions or syrups, and may be water, liquid paraffin, etc., which are commonly used simple diluents, and may be in the form of wetting agents, sweeteners, Excipients may also be included. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, or emulsions. Examples of the non-aqueous solvent and the suspending agent include vegetable oils such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate.

The preferred dose of the compound of the present invention varies depending on the age, sex, weight, symptom, degree of disease, drug form, route of administration, or duration of the subject, but can be appropriately selected by a person skilled in the art. However, for the desired effect, the pharmaceutical composition of the present invention is preferably administered at 0.0001 to 100 mg / kg per day. The administration can be done once a day, or divided into several times. In addition, the dose may be increased or decreased according to age, sex, weight, degree of disease, route of administration, and the like. Accordingly, the dosage is not limited in any way to the scope of the present invention.

The present invention provides a collagen synthesis promoter comprising the above loganic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The loganic acid of the present invention promotes the synthesis of collagen of type 1 and type 3 of the fibroblasts of the skin, which is safe to the living body, thereby improving skin elasticity and improving skin wrinkles, Is used as an active ingredient.

The loganic acid contained as an active ingredient of the collagen synthesis promoter may be included in an amount of 0.00001 to 99.9% by weight based on the total weight of the accelerator, and may be included in the total amount.

The present invention also provides a method for improving skin wrinkles or improving skin elasticity by applying a composition comprising loganic acid as an active ingredient to the skin.

The cosmetic, food or pharmaceutical composition of the present invention contains loganic acid having strong collagen synthesis promoting activity of type I and type III, and is excellent in skin wrinkle improvement and skin elasticity enhancement effect.

Rosicanoic acid is excellent in stability and is harmless to human body. Cosmetic, food or pharmaceutical composition containing it is easy to formulate and has excellent formulation stability.

Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.

Example 1 Confirmation of Promoting Synthesis of Type I Collagen of Loganic Acid in Human Fibroblasts

The addition of loganic acid to the culture medium of human - derived fibroblasts confirmed the promotion of type I collagen synthesis at the cellular level. The synthesized collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit). The loganic acid used in the experiment was purchased from Sigma Aldrich, USA.

The concentrations of the loganic acid samples used in the experiments were not toxic to human fibroblasts treated at the concentration of 1 μg / ml, 10 μg / ml was used. Cell viability was performed according to the test method provided using CCK-8 (cell counting kit-8, Dojindo Laboratories). The cytotoxicity results are shown in Table 1 below.

Roganic acid (/ / ml) Cell viability (%) 0 100 One 103 10 97 100 74

In order to measure the amount of collagen synthesis, loganic acid was added to the culture medium of fibroblasts (DMEM medium) and cultured for 48 hours. Then, the culture solution was taken and the degree of type 1 collagen synthesis was measured at each concentration using a PICP EIA kit And measured at 450 nm using a photometer.

For the comparison of the effects, the degree of collagen synthesis was measured in the same manner for the samples in which the culture medium of the untreated fibroblasts (negative control) and the vitamin C (positive control) were added to a final concentration of 52.85 / / ml. The increase rate of collagen production was calculated as a ratio of relative collagen production to the control group, and the results are shown in Table 2 below.

sample Type 1 collagen production (ng / ml) Growth rate (%) Negative control group 150.2 - Positive control (vitamin C) 246.8 64.3 1 g / ml of rosin acid 187.5 24.8 Roganic acid 10 / / ml 247.0 64.4 (Number of repetitions = 4)

As can be seen from the results in Table 2, loganic acid increased collagen synthesis in a concentration-dependent manner, and it was found that similar collagen synthesis at a lower concentration than that of vitamin C, which is generally known to induce collagen synthesis, Effect.

Example 2 Confirmation of Promoting Synthesis of Type III Collagen of Loganic Acid in Human Fibroblasts

Loganic acid was added to the culture medium of human - derived fibroblasts to confirm the promotion of the synthesis of type - 3 collagen at the cellular level. The synthesized collagen was quantitated using an EIA kit (Enzyme-linked Immunosorbent Assay Kit) for collagen type III.

The final concentration of loganic acid in the experiment was 1 ㎍ / ml and 10 ㎍ / ml. The loganic acid was added to the culture medium of human fibroblast (DMEM medium) for 48 hours, and the culture solution was taken. The degree of collagen synthesis at each concentration was measured with an EIA kit using a spectrophotometer 450 nm.

For the comparison of effects, the degree of synthesis of type 3 collagen was measured in the same manner for the sample to which the culture medium (negative control) and the vitamin C (positive control) were added so as to have a final concentration of 52.85 / / ml without any addition of fibroblasts Respectively.

The increase rate of collagen production was calculated as a ratio of relative collagen production to the control group, and the results are shown in Table 3 below.

sample Type 3 collagen production (ng / ml)) Growth rate (%) Negative control group 1091.8 - Positive control (vitamin C) 1321.5 21.0 1 g / ml of rosin acid 1940.4 77.7 Roganic acid 10 / / ml 2159.9 97.8 (Number of repetitions = 4)

As can be seen from the results in Table 3, loganic acid showed an excellent collagen synthesis effect by increasing type-III collagen in a concentration-dependent manner compared to a negative control without substance treatment.

Production Example 1 and Comparative Example 1: Production of ointment for external use

Skin ointments containing loganic acid as an active ingredient were prepared according to a conventional method as shown in the composition of Table 4 below. In addition, the ointment for external use for skin prepared from the other ingredients except for the active ingredient was prepared in Comparative Example 1.

Composition (% by weight) Production Example 1 Comparative Example 1 Rogacinic acid 0.2 0 Diethyl sebacate 8 8 Nonsense 5 5 Polyoxyethylene oleyl
Ether phosphate 6 6 Sodium benzoate One One vaseline to 100 to 100

Production Example 2 and Comparative Example 2: Production of cosmetic essence

Comparative Example 2 was prepared in the same manner as in Preparation Example 2, except that the formulation of the cosmetic essence containing loganic acid as an active ingredient was prepared in Preparation Example 2, The detailed composition is shown in Table 5 below.

Composition (% by weight) Production Example 2 Comparative Example 2 Rogacinic acid 0.5 0 glycerin 10.0 10.0 Sodium hyaluronate aqueous solution (1%) 5.0 5.0 Polyoxyethylene hardened castor oil 1.0 1.0 Methyl paraoxybenzoate 0.1 0.1 Spices 0.05 0.05 Purified water to 100 to 100

Production Example 3 and Comparative Example 3: Production of cosmetic cream

Comparative Example 3 was prepared in the same manner as in Preparation Example 3 except that the formulation of the cosmetic cream containing loganic acid as an active ingredient was prepared in the same manner as in Preparation Example 3 except that the active ingredient was not included. The detailed composition is shown in Table 6 below.

Composition (% by weight) Production Example 2 Comparative Example 2 Rogacinic acid 0.2 0 Stearic acid 15.0 15.0 ethanol 1.0 1.0 Potassium hydroxide 0.7 0.7 glycerin 5.0 5.0 Propylene glycol 3.0 3.0 antiseptic Suitable amount Suitable amount incense Suitable amount Suitable amount Purified water to 100 to 100

Example 3: Confirmation of skin wrinkle improvement effect through panel test

For the essences of Preparation Example 2 and Comparative Example 2, the skin wrinkle-reducing effect was tested as follows for healthy 35- to 50-year-old women.

30 women aged 35 to 50 years were divided into two groups by 15 persons, Group 1 was the essence of Preparation Example 2 containing 0.5% of loganic acid, Group 2 was the essence of Comparative Example 2 It was applied once a day for 3 months to the facial area. After 3 months, the improvement of skin wrinkles was evaluated by questionnaires. The subjects' questionnaires were judged to be three stages of improvement of the wrinkles of the skin, no improvement, slight improvement and considerable improvement as compared with before use, and the results are shown in Table 7 below.

Category (persons) No improvement Slight improvement A significant improvement Production Example 2 2 6 7 Comparative Example 2 10 4 One

As can be seen from the above Table 7, when the essence of Production Example 2 containing 0.5% by weight of loganic acid was used, it was confirmed that the effect of improving skin wrinkles was superior to that of the essence of Comparative Example 2 which was not used there was.

Example 4: Effect of wrinkle improvement test of cosmetic essence through image analysis

The wrinkle-improving effect was evaluated for the essences of Preparation Example 2 and Comparative Example 2 through image analysis. Specifically, the replica under the eye was sampled (Xantopren, Bayer) before the experiment was started, and the replica was sampled from the same site under the eyes immediately after the experiment was completed. The density of skin wrinkles was measured by analysis. The reduction rate of the skin wrinkle density by image analysis is a value obtained by averaging the ratio of the skin wrinkle density after use to the skin wrinkle density before use of the essence, and the measurement results are shown in Table 8 below.

Skin Wrinkle Density Reduction (%) Comparative Example 2 11 Production Example 2 47

As can be seen from the above Table 8, in the case of using the essence of Production Example 2 containing loganic acid, the effect of improving the wrinkles of the skin was better than that of the essence of Comparative Example 2 which did not contain loganic acid . No skin irritation or side effects due to the essence of Preparation Example 2 were found in the above test procedure.

Example 5: Test for improving skin elasticity of cosmetic cream

In order to apply the skin elasticity-enhancing effect of the cosmetic composition containing the loganic acid of the present invention to human skin, the creams of Preparation Example 3 and Comparative Example 3 were applied in a constant temperature and humidity chamber at 22 ° C and a relative humidity of 50% After applying for 4 weeks to 30 healthy adults, the elasticity of skin before and after application was measured and compared. In the left side of the subject's neck, Preparation Example 3 cream was used, and in the right side, Comparative Example 3 cream was used twice a day in morning and evening after cleansing for 4 weeks. After that, the degree of improvement of elasticity at each site was measured using a skin elasticity meter (cutometer, C + K, Germany). The degree of improvement was used as a parameter of Ur / Uf.

Elasticity improvement rate (%, n = 30) Comparative Example 3 4.23 Production Example 3 18.05

As can be seen from the above Table 9, when the cream of Preparation Example 3 containing loganic acid was used, the skin elasticity improvement effect was better than that of the cream of Comparative Example 3 which did not contain loganic acid It can be seen that it is excellent. In addition, skin irritation or side effects caused by the cream of Preparation Example 3 were not found in the above test procedure.

Claims (5)

A cosmetic composition comprising loganic acid as an active ingredient. A cosmetic composition for improving skin wrinkles or skin elasticity comprising loganic acid as an active ingredient. The cosmetic composition according to claim 1 or 2, wherein the loganic acid is contained in an amount of ¹ × 10 ^-6 to 10% by weight based on the total weight of the cosmetic composition. Collagen synthesis promoter containing loganic acid as an active ingredient. A method for improving skin wrinkles or improving skin elasticity by applying a composition comprising loganic acid as an active ingredient to skin.